Skip to main content

View full-text article in PMC

. 2022 Dec 8;45(1):29–43. doi: 10.1007/s11357-022-00705-1

Table 1.

Participant characteristics at baseline for the placebo and three NMN-treated groups

	NMN supplementation
	Placebo, n = 20^e	300 mg, n = 20	600 mg, n = 20	900 mg, n = 20^e	p 300/P^g	p 600/P^g	p 900/P^g
Age (year)^a	46.5 ± 6.7	51.2 ± 7.0	49.5 ± 6.7	49.9 ± 6.3	0.04	0.17	0.11
Female (n)^b	12	10	14	11	0.53	0.16	0.48
Weight (kg)^a	66.2 ± 13.5	69.2 ± 13.2	66.4 ± 10.5	66.8 ± 9.8	0.73	0.96	0.87
Height (cm)^a	157 ± 8	159 ± 10	157 ± 10	157 ± 8	0.44	0.96	0.83
BMI (kg/m²)^a	26.9 ± 4.9	27.4 ± 4.8	27.1 ± 3.9	26.9 ± 4.9	0.76	0.89	0.99
NAD (nM)^c,f	8.11 ± 5.16	11.8 ± 11.7	7.95 ± 3.29	10.5 ± 6.8	0.20	0.91	0.22
Six-minute walking (m)^c	325 ± 144	307 ± 108	290 ± 92	323 ± 113	0.66	0.36	0.97
Blood biological age (years)^a	39.8 ± 7.2	42.2 ± 6.0	45.2 ± 6.5	44.3 ± 7.3	0.27	0.17	0.57
Fasting insulin (mIU/mL)^a	18.1 ± 15.7	15.5 ± 7.2	15.1 ± 10.1	16.1 ± 9.7	0.49	0.47	0.62
Fasting glucose (mg/dL)^a	87.1 ± 21.4	88.6 ± 8.6	94.9 ± 22.5	94.8 ± 17.3	0.77	0.26	0.21
HOMAR-IR^d	1.41 ± 0.79	2.28 ± 1.43	1.70 ± 1.05	2.01 ± 1.26	0.25	0.94	0.43
SF-36 (score)^c	122 ± 14	124 ± 13	118 ± 16	122 ± 17	0.95	0.40	0.95

^aData are “mean ± SD”. Student t test was used for comparison over placebo

^bChi-square t test was used for comparison over placebo

^cData are “mean ± SD”. Mixed model for repeated measures (MMRM) was used for comparison over placebo

^dData are “mean ± SD”. Mann–Whitney U test was used for comparison over placebo

^eDue to 1 participant from placebo and 900 mg groups did not fast, HOMA-IR was based on 19 participants for these two groups

^fBlood NAD concentration data are the total concentration of “NAD⁺ + NADH” in serum

^gStatistical significance was set at p < 0.05